LL-37 Antimicrobial Mechanisms: TLR4, Membrane Disruption, Wound Healing and the Psoriasis Paradox | QSC

Why bacteria struggle to develop resistance to LL-37

Conventional antibiotics target specific proteins — single amino acid mutations can confer resistance. LL-37 targets the physical composition of the membrane itself. To become resistant, bacteria would need to fundamentally restructure their membrane phospholipid composition — changes that are costly to fitness. This physical mechanism makes LL-37 and AMPs broadly a target for next-generation anti-infective research, particularly against MRSA and multidrug-resistant Gram-negative organisms.

LL-37 in sepsis research

In LPS-challenged rodent models, LL-37 reduces plasma TNF-alpha, IL-6, and IL-10 when administered prior to or concurrent with LPS. It also directly binds and neutralises lipoteichoic acid (LTA) from Gram-positive bacteria — the TLR2 activating equivalent of LPS. This dual LPS/LTA neutralisation makes LL-37 the tool for studying pattern recognition receptor-independent endotoxin clearance in sepsis models, complementary to TLR4 antagonist approaches.

VEGF receptor transactivation

LL-37 activates VEGFR2 on endothelial cells via EGFR-dependent transactivation — driving endothelial cell migration, proliferation, and tube formation (angiogenesis). In diabetic mouse punch biopsy models, LL-37 topical application accelerates wound closure and increases CD31+ vascular density at the wound edge. This angiogenic mechanism is independent of its antimicrobial activity and operates at sub-antimicrobial concentrations.

Keratinocyte migration and re-epithelialisation

LL-37 activates EGFR on keratinocytes directly → ERK1/2 → keratinocyte migration. In scratch assay models, LL-37 1-10 µM accelerates wound closure velocity by ~50% vs vehicle. Combined with its antimicrobial activity at the wound site, this makes LL-37 a dual-mechanism wound healing research compound — reducing infection burden while simultaneously stimulating tissue repair.

LL-37 as an autoimmune initiator

Overproduced LL-37 forms complexes with self-DNA released from damaged/dying keratinocytes. These LL-37/DNA complexes are taken up by plasmacytoid dendritic cells (pDCs) via FcγRIIa. Inside pDCs, LL-37 protects DNA from degradation and presents it to endosomal TLR9 → type I IFN production. Type I IFNs then activate myeloid DCs, which present self-antigens to T cells → adaptive immune response against skin antigens. This is a classic example of an innate immune peptide co-opted into initiating adaptive autoimmunity. Research in IMQ psoriasis models uses LL-37 to study this pDC/TLR9/IFN axis.

What makes LL-37 selective for bacterial membranes?

Bacterial membranes contain high proportions of anionic phospholipids (phosphatidylglycerol, cardiolipin). Mammalian cell membranes are dominated by neutral phosphatidylcholine on the outer leaflet. LL-37’s cationic residues electrostatically attract to anionic bacterial membranes, concentrating the peptide at bacterial surfaces while mammalian cells are relatively protected.

Can bacteria develop resistance to LL-37?

Resistance is possible but costly. Some bacteria (S. aureus, P. aeruginosa) modify membrane phospholipid composition (reducing anionic charge) or secrete proteases that degrade LL-37. However, these adaptations require significant metabolic investment and reduce bacterial fitness in non-LL-37 environments. Physical membrane targeting is fundamentally harder to resist than enzyme or receptor targeting.

Why does LL-37 cause inflammation in psoriasis if it is antimicrobial?

Context-dependence. At normal skin levels, LL-37 is antimicrobial. In psoriatic skin, keratinocyte injury releases large amounts of LL-37 and self-DNA simultaneously. LL-37 complexes with self-DNA, protecting it from DNase and delivering it to pDC TLR9 — triggering type I IFN production and initiating autoimmune inflammation.

What research models are most useful for LL-37?

MIC/MBC assays (MRSA, P. aeruginosa, ESKAPE pathogens), LPS neutralisation and cytokine reduction in macrophage/monocyte cultures, LPS sepsis model in mice, scratch assay and diabetic punch biopsy for wound healing, and IMQ psoriasis model for the pDC/TLR9/IFN autoimmune axis.